Full insulin line (regular, NPH, biphasic, glargine) plus modern SGLT2 inhibitors — dapagliflozin, empagliflozin, canagliflozin.
Over 530 million adults live with diabetes, and the WHO targets 100% insulin access for all who need it. Artemisine Medicines Technology manufactures the complete human insulin family — regular human insulin, isophane (NPH) and biphasic 30/70 premixed formulations at 100 IU/mL — plus the long-acting analogue insulin glargine, covering basal-bolus and premix regimens from a single GMP sterile site.
For type 2 diabetes we supply the modern SGLT2 inhibitor class: dapagliflozin 10 mg, empagliflozin 25 mg and canagliflozin 300 mg tablets — agents with proven cardiovascular and renal outcome benefits in international guidelines. Related products include glucose/dextrose IV infusions for hypoglycaemia rescue and clinical nutrition support.
Insulin quality depends on the cold chain: our export operation runs validated 2–8°C packaging with temperature data-loggers, and every batch ships with COA, COPP, DMF and CTD dossiers for national registration and hospital tenders.
All products are GMP manufactured and supplied with COA, COPP, DMF and CTD dossiers. Tap any product for specifications and WHO prescribing guidance.
Tell us your target market and annual volume — our export team replies within 24 hours.
Human insulin injection (regular) 100 IU/mL, isophane protamine (NPH) human insulin, mixed protamine human insulin (biphasic 30/70) and insulin glargine 100 IU/mL — covering basal, bolus and premix therapy.
Yes — the SGLT2 inhibitor class: dapagliflozin 10 mg, empagliflozin 25 mg and canagliflozin 300 mg tablets, all GMP manufactured with full registration documentation.
Validated 2–8°C insulated packaging with calibrated temperature data-loggers, cold-store staging at origin and reefer/air-freight options — qualification reports available for your regulatory file.
Artemisine Medicines